A new fight is brewing over the Medicare drug price negotiation program after the Trump administration proposed to consider ...

As many have now heard, on Thursday, August 15, 2024, the Centers for Medicare & Medicaid Services (CMS) released the prices for the first 10 prescription drugs selected for negotiation with ...

In September 2023, CMS published a list of 10 selected drugs covered under Medicare Part D for the first cycle of negotiations and engaged in voluntary negotiations with the drug companies for the ...

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f ...

The CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top of the list of drugs for which Medicare will the negotiate the price of in 2025. The list price for a one ...

Certain exemptions from the Medicare drug price negotiation program could have unintended consequences on pharmaceutical innovation, particularly for small biotech companies and patients with rare ...

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

The Centers for Medicare & Medicaid Services (CMS) rolled out guidance Oct. 2 as stakeholders prep for the second round of the drug price negotiation program. | CMS is looking to increase feedback ...

CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026.

The Centers for Medicare & Medicaid Services plans to negotiate the prices for 15 new drugs, although it says its seeking "greater transparency" in drug price talks.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of ...